Trulicity class
Pro Research Analysisby 
Searched over 200M research papers for "trulicity class"
Trulicity (Dulaglutide) Class Overview
Introduction to Dulaglutide (Trulicity)
Dulaglutide, marketed under the brand name Trulicity, is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly and Company for the treatment of type 2 diabetes mellitus (T2DM) . This medication is designed to be administered once weekly via subcutaneous injection, making it a convenient option for patients managing their blood glucose levels .
Mechanism of Action: GLP-1 Receptor Agonist
Dulaglutide functions by mimicking the incretin hormone GLP-1, which enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon release, and slows gastric emptying. This results in improved glycemic control and potential weight loss Edwards2015Scheen2016. The drug consists of a GLP-1 analogue linked to a human IgG4-Fc heavy chain, which protects it from degradation by dipeptidyl peptidase-IV, thereby prolonging its activity .
Efficacy and Safety Profile
Glycemic Control and Weight Loss
Clinical trials have demonstrated that dulaglutide effectively lowers glycated hemoglobin (A1c), fasting, and postprandial glucose levels. It has shown superior glucose-lowering activity compared to metformin, sitagliptin, exenatide, and insulin glargine, and is non-inferior to liraglutide Scheen2016Aj2016. Additionally, dulaglutide promotes weight loss, which is a beneficial effect for many patients with T2DM .
Cardiovascular Benefits
Dulaglutide has been associated with cardiovascular benefits, including lower blood pressure and improved lipid profiles. These effects contribute to its overall safety and efficacy in managing T2DM .
Adverse Effects
The adverse effect profile of dulaglutide is similar to other GLP-1 receptor agonists, with common side effects including transient gastrointestinal issues such as nausea and diarrhea. There is also a potential risk for pancreatitis, although this is relatively low .
Place in Therapy
First- and Second-Line Therapy
Dulaglutide is approved for use as both a first-line therapy, potentially replacing metformin, and as a second-line therapy in combination with other medications such as metformin, sulfonylureas, or pioglitazone Edwards2015Scheen2016. It is particularly useful for patients who have not achieved adequate glycemic control with monotherapy.
Combination Therapy
In the AWARD clinical trial program, dulaglutide was effective in patients treated with diet and exercise alone, as well as in combination with other antidiabetic agents, including metformin, sulfonylureas, and prandial insulin Scheen2016Aj2016. This flexibility makes it a versatile option in the management of T2DM.
Conclusion
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist that offers significant benefits in the management of type 2 diabetes mellitus. Its efficacy in lowering blood glucose levels, promoting weight loss, and providing cardiovascular benefits, along with its convenient dosing schedule, positions it as a valuable option for both first- and second-line therapy in T2DM management Sanford2014Edwards2015Scheen2016+1 MORE.
Sources and full results
Most relevant research papers on this topic